BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment

BiomX doses first patient in Phase 2b trial of BX004 in CF - BioTuesdays

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa) infections—a leading cause of death in this patient population despite modern treatments. According to BiomX, pending topline results expected in the first quarter of 2026, BX004 could potentially be positioned…

BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment

BiomX has dosed the first subject in the randomised Phase IIb trial of the multi-phage therapy, BX004, to treat cystic fibrosis (CF).The post BiomX doses first subject in Phase IIb trial of cystic fibrosis treatment appeared first on Clinical Trials Arena.